Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: Results from major clinical trials

Clinical Cornerstone

Volumn 6, Issue 4, 2004, Pages 53-63

  Black, Henry R ^a   Charles, J ^a   Roberts, Margaret ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ADJUVANT THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; META ANALYSIS; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

EID: 15444374457     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)80078-4     Document Type: Article

References (12)

1. Psaty B.M. Heckbert S.R. Koepsell T.D. e al. The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 224 1995 620-625
2. Abascal V.M. Larson M.G. Evans J.C. et al. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study Arch Intern Med. 158 1998 1882-1886
3. Staessen J.A. Fagard R. Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The SystolicHypertension in Europe (Syst-Eur) Trial Investigators Lancet 350 1997 757-764
4. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: Results of prospectively designed overviews of randomized trials Lancet 355 2000 1955-1964
5. ALLRAT Officers and Coordinators for the ALLRAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. TheAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLRAT) JAMA 288 2002 2981-2997
6. ALLRAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatmentto Prevent Heart Attack Trial (ALLRAT) JAMA 283 2000 1967-1975
7. Yusuf S. Sleight P. Pgoue J. et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study investigators N Engl J Med. 342 2000 145-153
8. Eisenberg M.J. Brox A. Bestawros A.N. Calcium channel blockers: An update Am J Med. 116 2004 35-43
9. Hansson L. Hedner T. Lund-Hohansen P. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockes on cardiovascular morbidity and mortality inhypertension: The Nordic Diltiazem (NORDIL) study Lancet 356 2000 359-365
10. Black H.R. Elliott W.J. Grandits G. et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial JAMA 289 2003 2073-2082
11. Pepine C.J. Handberg E.M. Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coro nary artery disease. The International Verapamil Trandolapril Study (INVEST): A randomized controlled trial JAMA 290 2003 2805-2816
12. Chobanian A.V. Bakris G.L. Black H.R. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood. Pressure: The JNC 7 Report JAMA 289 2003 2560-2571